Newron Pharmaceuticals SpA (XSWX:NWRN) Growth Rank: 9 (As of Aug. 26, 2026) — 125% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NWRN Newron Pharmaceuticals SpA XSWX:NWRN
75 GF Score
Price CHF12.48
GF Value CHF13.31
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Growth Rank?

Newron Pharmaceuticals SpA XSWX:NWRN +2.30% 75 Growth Rank is 9 as of Aug. 26, 2026, which is 125% above its 10-year median of 4.00. GuruFocus rates XSWX:NWRN with a GF Score™ of 75/100 and a GF Value™ of CHF13.31 (Fairly Valued). The stock has 5 warning signs investors should review.

Newron Pharmaceuticals SpA has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Newron Pharmaceuticals SpA Growth Rank Related Terms

XSWX:NWRN vs VRTX, REGN, RVMD: Growth Rank Comparison

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Newron Pharmaceuticals SpA Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Growth Rank distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's Growth Rank falls into.


XSWX:NWRN
75GF Score
Newron Pharmaceuticals SpA XSWX:NWRN
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
Newron Pharmaceuticals SpA (XSWX:NWRN) has a Growth Rank of 9 as of Aug. 26, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Newron Pharmaceuticals SpA and its competitors. This is 125% above median its historical median of 4.00. Over the past decade, Newron Pharmaceuticals SpA's Growth Rank has ranged from 1.00 to 10.00.
Is Newron Pharmaceuticals SpA's Growth Rank too high?
Newron Pharmaceuticals SpA's current Growth Rank of 9 is 125% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Growth Rank compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Growth Rank of 9 can be compared against companies in the Biotechnology industry. Historically, Newron Pharmaceuticals SpA's own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Growth Rank is 9, which is 125% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XSWX:NWRN) is currently considered Fairly Valued. The stock's GF Value™ is CHF13.31, compared to a current price of CHF12.48 — trading 6.2% below its estimated fair value. The current Growth Rank is 9, which is 125% above median its 10-year median of 4.00. Newron Pharmaceuticals SpA's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XSWX:NWRN), the current Growth Rank is 9 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of CHF12.48 is trading 6.2% below its estimated GF Value™ of CHF13.31. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for XSWX:NWRN:

  • Growth Rank: 9 (125% above median its 10-year median of 4.00)
  • GF Value™: CHF13.31 vs. price of CHF12.48 (6.2% below fair value)
  • GF Score™: 75/100 with 5 warning signs

No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Other Exchanges NWRNz:UK0QOI:UKNP5:Germany
Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
75GF Score

Get the complete analysis for XSWX:NWRN

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF12.48
Price
CHF13.31
GF Value